Lack of Association Between Heart Failure and Incident Cancer

• Published in: Journal of the American College of Cardiology 2018-04, Vol.71 (14), p.1501-1510
• Main Authors: Selvaraj, Senthil, Bhatt, Deepak L., Claggett, Brian, Djoussé, Luc, Shah, Sanjiv J., Chen, Jiaying, Imran, Tasnim F., Qazi, Saadia, Sesso, Howard D., Gaziano, J. Michael, Schrag, Deborah
• Format: Article
• Language: English
• Subjects: Adult; Age; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Aspirin; Aspirin - administration & dosage; beta Carotene - administration & dosage; Cancer; Cardiology; Cardiovascular disease; Clinical trials; Colorectal cancer; Confidence intervals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enrollments; Family medical history; Female; Follow-Up Studies; Forecasting; Health risk assessment; Health risks; Heart attacks; Heart diseases; Heart failure; Heart Failure - complications; Heart Failure - prevention & control; Humans; Incidence; incident cancer; Laboratories; Leukemia; Male; malignancy; Medical diagnosis; Medical personnel; Medical screening; Mens health; Middle Aged; Mortality; Neoplasms - epidemiology; Neoplasms - etiology; Neoplasms - prevention & control; Obesity; Physicians; Prognosis; Prostate cancer; Provitamins - administration & dosage; Retrospective Studies; Risk Assessment - methods; Risk Factors; Sensitivity analysis; Skin cancer; Smoking; Statistical analysis; Studies; Surveillance; Survival Rate - trends; tumor; United States - epidemiology
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2018.01.069

Several recent studies have suggested an increased cancer risk among patients with heart failure (HF). However, these studies are constrained by limited size and follow-up, lack of comprehensive data on other health attributes, and adjudicated cancer outcomes. This study sought to determine whether HF is associated with cancer incidence and cancer-specific mortality. The study assembled a cohort from the Physicians’ Health Studies I and II, 2 randomized controlled trials of aspirin and vitamin supplements conducted from 1982 to 1995 and from 1997 to 2011, respectively, that included annual health evaluations and determination of cancer and HF diagnoses. In the primary analysis, the study excluded participants with cancer or HF at baseline and performed multivariable-adjusted Cox models to determine the relationship between HF and cancer, modeling HF as a time-varying exposure. In a complementary analysis, the study used the landmark method and identified cancer-free participants at 70 years of age, distinguishing between those with and without HF, and likewise performed Cox regression. Sensitivity analyses were performed at 65, 75, and 80 years of age. Among 28,341 Physicians’ Health Study participants, 1,420 developed HF. A total of 7,363 cancers developed during a median follow-up time of 19.9 years (25th to 75th percentile: 11.0 to 26.8 years). HF was not associated with cancer incidence in crude (hazard ratio: 0.92; 95% confidence interval: 0.80 to 1.08) or multivariable-adjusted analysis (hazard ratio: 1.05; 95% confidence interval: 0.86 to 1.29). No association was found between HF and site-specific cancer incidence or cancer-specific mortality after multivariable adjustment. Results were similar when using the landmark method at all landmark ages. HF is not associated with an increased risk of cancer among male physicians. [Display omitted]